R. Swann

发表

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

V. Rusch, R. Livingston, D. Gandara, 2009, The Lancet.

An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).

A. Hauschild, C. Blank, W. Miller, 2013 .

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.

Nasser Altorki, A. Reeves, D. Yankelevitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.

Robert L. White, D. Brachman, N. Lee, 2006, The journal of supportive oncology.

Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13.

A. Garden, K. Ang, C. Takita, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309)

Michael R. Green, D. Gandara, F. Shepherd, 2005 .

Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.

Benjamin Movsas, D. Ettinger, R. Komaki, 2005, International journal of radiation oncology, biology, physics.

Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.

Keith R Abrams, Nicholas R Latimer, K. Abrams, 2015, The oncologist.

Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer.

Maria Werner-Wasik, Jeffrey Bradley, William Sause, 2008, International journal of radiation oncology, biology, physics.

Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience.

W. Curran, R. Komaki, W. Sause, 2005, International journal of radiation oncology, biology, physics.

Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.

A. Hauschild, C. Blank, P. Rutkowski, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.

R. Komaki, L. Mell, A. Mundt, 2007, International journal of radiation oncology, biology, physics.

Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC).

R. Swann, R. Amado, D. Rajagopalan, 2010 .

Pre-treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: An RTOG analysis.

A. Garden, K. Ang, R. Weber, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis.

K. Abrams, R. Swann, M. Amonkar, 2013 .

Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)

A. Hauschild, D. Schadendorf, P. Ascierto, 2012 .

Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).

D. Schadendorf, P. Ascierto, A. Ribas, 2014 .